Ruggiero S Saxena D Tetradis S Aghaloo T Ioannidou E.

Task Force on Design and Analysis in Oral Health Research: Medication-Related Osteonecrosis of the Jaw.

JDR Clin Trans Res. 2018; 3: 222-225https://doi.org/10.1177/2380084418770662Marx RE Sawatari Y Fortin M et al.

Bisphosphonate induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.

J Oral Maxillofac Surg. 2005; 63: 1567-1575

Previously successful dental implants can fail when patients commence anti-resorptive therapy-a case series.

Int J Oral Maxillofac Surg. 2018; 47: 220-222https://doi.org/10.1016/j.ijom.2017.07.012Khan AA Morrison A Hanley DA et al.

Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus.

J Bone Miner Res. 2015; 30: 3-23https://doi.org/10.1002/jbmr.2405Lopes RN Rabelo GD Rocha AC Carvalho PA Alves FA.

Surgical Therapy for Bisphosphonate-Related Osteonecrosis of the Jaw: Six-Year Experience of a Single Institution.

J Oral Maxillofac Surg. 2015; 73: 1288-1295https://doi.org/10.1016/j.joms.2015.01.008

Epstein MS, Wicknick FW, Epstein JB, Berenson JR, Gorsky M. Management of bisphosphonate-associated osteonecrosis: pentoxifylline and tocopherol in addition to antimicrobial therapy. An initial case series. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;110(5):593-596. doi:10.1016/j.tripleo.2010.05.067.

Pentoxifylline and tocopherol in the treatment of yearly zoledronic acid-related osteonecrosis of the jaw in a corticosteroid-induced osteoporosis.

J Oral Maxillofac Surg. 2014; 72: 334-337https://doi.org/10.1016/j.joms.2013.06.188

Owosho AA, Estilo CL, Huryn JM, Yom SK. Pentoxifylline and tocopherol in the management of cancer patients with medication-related osteonecrosis of the jaw: an observational retrospective study of initial case series. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;122(4):455-459. doi: 10.1016/j.oooo.2016.06.019.

Heifetz-Li JJ, Abdelsamie S, Campbell CB, Roth S, Fielding AF, Mulligan JP. Systematic review of the use of pentoxifylline and tocopherol for the treatment of medication-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019;128(5):491-497.e2. doi:10.1016/j.oooo.2019.08.004.

Famoso JM Laughlin B McBride A Gonzalez VJ.

Pentoxifylline and vitamin E drug compliance after adjuvant breast radiation therapy.

Adv Radiat Oncol. 2017; 3: 19-24https://doi.org/10.1016/j.adro.2017.09.004Yarom N Shapiro CL Peterson DE Van Poznak CH Bohlke K Ruggiero SL Migliorati CA Khan A Morrison A Anderson H Murphy BA Alston-Johnson D Mendes RA Beadle BM Jensen SB Saunders DP

Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline.

J Clin Oncol. 2019; 37 (1): 2270-2290https://doi.org/10.1200/JCO.19.01186

Previously successful dental implants can fai when patients commence anti-resorptive therapy-a case series.

Int J Oral Maxillofac Surg. 2018; 47: 220-222https://doi.org/10.1016/j.ijom.2017.07.012Dawson DL Cutler BS Hiatt WR Hobson 2nd, RW Martin JD Bortey EB Forbes WP Strandness Jr, DE.

A comparison of cilostazol and pentoxifylline for treating intermittent claudication.

Am J Med. 2000; 109: 523-530https://doi.org/10.1016/s0002-9343(00)00569-6

Comparative Effects of Cilostazol and Other Therapies for Intermittent Claudication. Comparative effects of cilostazol and other therapies for intermittent claudication.

Am J Cardiol. 2001; 87: 19D-27Dhttps://doi.org/10.1016/s0002-9149(01)01673-3Money SR Herd JA Isaacsohn JL Davidson M Cutler B Heckman J Forbes WP.

Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease.

J Vasc Surg. 1998; 27: 267-274https://doi.org/10.1016/s0741-5214(98)70357-xBeebe HG Dawson DL Cutler BS Herd JA Strandness Jr., DE Bortey EB Forbes WP.

A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial.

Arch Intern Med. 1999; 159: 2041-2050https://doi.org/10.1001/archinte.159.17.2041

Serum VEGF levels as predictive marker of bisphosphonaterelated osteonecrosis of the jaw.

J. Hematol. Oncol. 2012; 5: 56